Icosapent Ethyl and Atherosclerotic Cardiovascular Disease in Type 2 Diabetes (Narrative Review)

Abstract

This narrative review was aimed to analyze the current views on the biochemical and molecular mechanisms of ω-3 polyunsaturated fatty acids (ω-3 PUFAs), in particular icosapent ethyl (IPE), in atherosclerotic cardiovascular disease (ASCVD) and type 2 diabetes mellitus (T2D). The results of experimental, cohort, prospective, randomized clinical trials confirm the prospects of using IPE to prevent and treat ASCVD in T2D.
 Search Techniques. Databases from Scopus, Science Direct (from Elsevier), EBSCO, PubMed, and Medline were all searched. To find trials that were missed by the web search, a manual search of the publishing bibliographies was conducted.